Metabolism of androgens includes glucuronidation, the major pathway of steroid elimination in several steroid target tissues. Glucuronidation is catalysed by UDP-glucuronosyltransferases (UGTs). UGT2B17 has been shown to be particularly active against androgens and is highly abundant in the prostate. Recently, we discovered that deletion of the UGT2B17 gene is associated with low or undetectable urinary testosterone levels. Here, we determined the phenotypic outcome of the deletion by quantifying the UGT2B17 mRNA expression in normal prostate tissues in individuals with different genotypes. Additionally, the frequency of UGT2B17 deletion polymorphism was studied in a Swedish population-based case-control study including 176 patients diagnosed with prostate cancer and 161 controls. We found that the individuals homozygous for the insertion allele expressed 30 times more UGT2B17 mRNA in prostate tissue than the heterozygotes. Carriers of the deletion allele had a significantly increased risk of prostate cancer (OR ¼ 2.07; 95% CI ¼ 1.32-3.25). In conclusion, these results show the UGT2B17 deletion polymorphism is associated with prostate cancer risk.
Introduction
Prostate cancer is the most frequently diagnosed male cancer and the second leading cause of cancer deaths in North America. 1, 2 It was early observed that eunuchs (men lacking testosterone) do not develop prostate cancer 3 generating the theory that testosterone plays a vital role for the development and progression of the disease. As a corollary, testis ablation is well established and effective way to stop progression of the disease. 4 Finasteride, an agent that blocks the formation of dihydrotestoterone (DHT), the more potent form of testosterone, is widely used for treatment of benign prostate hyperplasia. In a large trial for prostate cancer prevention finasteride decreased the risk of prostate cancer by 25%, but contrary to the expectations, men in the finasteride group seemed to have more high-grade tumours. 5 The reason for this are unclear but it has been suggested that oestrogen receptor b (ERb) may have a role in this outcome. 6 Since androgens are known to play an important role in the development, function, and pathology of normal and malignant growth of prostate cells, it is important to study the genetic variation in the androgen metabolism and its contribution to the risk of prostate cancer.
Different ethnic groups differ in the risk to develop prostate cancer, Afro-Americans having the highest incidence followed by Caucasians and Asians having the lowest incidence. 7 Lower levels of testosterone metabolites such as androsterone glucuronide and androstanediol glucuronide were observed in plasma of Asian subjects. 8, 9 This finding was interpreted as a sign of lower androgen 'load', which may contribute to the lower incidence of prostate cancer in Asians. Studies indicate that environmental and lifestyle factors account for 10-15% of the racial differences in risk. 1 Uridine diphosphoglucuronosyl tranferases (UGTs) constitute a family of enzymes that glucuronidate a wide variety of substrates including exogenous and endogenous compounds such as bilirubin, bile acids and steroids. The glucuronidated product is more polar, water soluble and more easily excreted in the bile and urine. On the basis of homology of protein primary structure, the UGT enzymes have been grouped into two families, UGT1 and UGT2. 10 Enzymes of the UGT2 family are encoded by separate genes and are subdivided into two subfamilies, UGT2A and UGT2B. Seven functional UGT2B enzymes have been identified in humans to date, all of which are important in the homoeostasis and metabolism of steroids.
UGT2B17 is one of the UGT2B enzymes and is highly expressed in the prostate. 11 It has been found to have the highest activity for androsterone, testosterone and dihydrotestosterone 12 as compared with the other UGT2B members. Previous studies have demonstrated deletion of the UGT2B17 gene. 13, 14 We have demonstrated recently an association between the UGT2B17 deletion and urinary testosterone excretion. 15 Homozygous carriers of the deletion (del/del) allele have very low or undetectable levels of testosterone in the urine. The allele frequencies were also found to differ between ethnic groups, absence of the UGT2B17 gene being seven times more common among Koreans than Caucasians.
In this study, we examined the association between this polymorphism in the UGT2B17 gene and the risk of prostate cancer. Our study was made in a population-based casecontrol study among Swedish men. We also assessed if the del is associated with altered gene expression in the prostate.
Results

Characteristics of the cases and controls
The mean age of both cases and controls was 71 years. There were no significant differences between cases and controls regarding family history of prostate cancer (Table 1) . Clinical characteristics of the cases are given in Table 1 .
UGT2B17 genotyping
Genotyping results were obtained in all except two subjects. The observed genotype distribution in controls was no different from that expected under Hardy-Weinberg equilibrium. The frequency of UGT2B17 insertion (ins) allele in the control group was 0.81 as compared with 0.71 among the cases (Table 2 ). Relative to individuals homozygous for the ins allele, we found that individuals lacking one or two alleles were at significantly increased risk of prostate cancer (odds ratio (OR) ¼ 2.05). Adjustments for age did not change this association (Table 2) . All subjects with deletion, heterozygous (del/ins) and homozygous (del/del).
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There was no association between the UGT2B17 del allele and metastatic disease or high-grade tumour differentiation (data not shown).
Detection of UGT2B17 mRNA in prostate tissues by quantitative real-time PCR Gene expression of UGT2B17 was quantified in prostate tissues using real-time polymerase chain reaction (PCR).
Fifteen individuals were included in the study. Four individuals were heterozygous (del/ins) and 11 individuals were homozygous for the insertion allele (ins/ins).
As expected the expression of UGT2B17 was found to be significantly lower in prostate tissues derived from del/ins individuals as compared with ins/ins individuals (P ¼ 0.02, Mann-Whitney test; Figure 1 ). The ins/ins individuals exhibited approximately 30 times more UGT2B17 mRNA in the prostate tissues than individuals with only one del allele.
Discussion
Here we show that individuals with two copies of UGT2B17 gene have significantly lower risk of prostate cancer. Additionally, we found that the deletion of one allele is associated with significantly lower mRNA levels in the prostate, further supporting the epidemiological results that individuals exhibiting two gene copies of UGT2B17 are protected from androgen exposure in the prostate and have a decreased risk of developing prostate cancer. It was not possible to assess the relative risk for del/del individuals owing to the low numbers.
Our results are consistent with a previous report, which shows that Caucasian individuals homozygous for the del allele exhibit a significant increase risk for prostate cancer compared with insertion carriers (ins/ins and ins/del). 16 The genotyping method used in that study did not distinguish between heterozygous (ins/del) and homozygous (ins/ins) genotypes, so they were not able to compare the del carriers with individuals homozygous for the ins allele, as was the case in this report.
Another important enzyme involved in the inactivation of androgens in the prostate is UGT2B15. A functional single nucleotide polymorphism (Y85D) in the UGT2B15 gene has been associated with altered prostate cancer risk in epidemiological studies. The enzyme with Asp at position 85 exhibits a twofold decrease in enzyme activity for DHT 17 and is associated with a threefold increased risk of prostate cancer. 18, 19 These results are in line with the UGT2B17 results presented here, suggesting that the alleles associated with increased inactivation of androgens are associated with a decreased risk of prostate cancer.
The interethnic differences observed for the UGT2B17 polymorphism frequency are consistent with the ethnic distribution of the UGT2B15 Y85D polymorphism. On one hand, it is conceivable that an increased local enzymatic degradation in the prostate may decrease the androgen exposure of the androgen receptors thereby counteracting the postulated proliferative role of these receptors. On the other hand, UGT2B17 and UGT2B15 alleles that are associated with an increased risk of prostate cancer are more common in Asian populations than in Caucasians populations. Obviously, the genetic variation in UGT2B17 (and UGT2B15) does not explain the ethnic differences observed in prostate cancer that was discussed previously. 15 One limitation of this study is the small sample size. The reason that we could not find any association to tumour stage or differentiation grade may be owing to lack of power in our study and should be repeated in a larger population. The fact that the healthy controls used in this study was not screened for prostate cancer is not considered as a limitation. Even though prostate cancer was found among the controls, this would bias the results towards null. Another concern with this study is if the UGT2B17 mRNA levels correspond to the UGT2B17 protein expression. It has been reported that UGT2B17 is much more labile than UGT2B15 in LNCaP cells, 20 so it is possible that the 30 times difference observed in mRNA expression may not reflect the enzyme levels in the prostate. This needs further elucidation.
In conclusion, we have found that homozygous carriers of the UGT2B17 gene have significantly higher expression of the enzyme at the mRNA level in the prostate and lack of one allele of the gene is associated with doubled risk of prostate cancer.
Materials and methods
Study population and sample selection
The study design was a population-based case-control study of 337 Caucasians living in the county of Ö rebro in Sweden. The cases were 176 patients, age 51-79 years, with clinical and histological prostate cancer as defined in biopsy samples, were recruited consecutively between May 1994 and February 1996 from either of three hospitals in the county. Eighty-one percent agreed to participate. The controls were randomly selected every 3 months from the county population register and frequency matched for age (50-59, 60-69 and 70-79 years). They were asked to participate by mail and 161 individuals agreed to participate, giving a response rate of 79%. Risk factor information Figure 1 Relative UGT2B17 mRNA levels in prostate tissues. Quantification was performed using real-time PCR with cDNA obtained from 15 donors. 18S was used as an internal control for normalization. UGT2B17 mRNA levels in ins/ins were found to be significantly higher than in individuals absence of one allele.
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Genotyping of the UGT2B17 deletion
Genotyping was essentially performed as described previously. 13 The deletion-specific primers (J-markers) and the exon 6-specific primers (Table 3) were used in a standard PCR protocol (AmpliTaq DNA Polymerase, Applied Biosystems, Foster City, CA, USA) and the products were identified in a 2% agarose gel. Owing to low DNA concentrations, some of the samples were analyzed with SYBR green Master Mix (Applied Biosystems), and the product formations was followed on an ABI Prism7700 (Applied Biosystems). Additionally these products were also confirmed on a gel. In DNA samples from heterozygous individuals (del/ins), a product from both the reactions appeared. In individuals homozygous for the deletion allele (del/del), or homozygous for UGT2B17 insertion allele (ins/ins) only one product was observed with either the deletion-specific primers or the exon 6 primers, respectively.
Statistical analysis
Genotype associations were assessed with binary logistic regression using Minitab statistical software package (version 12.1, Minitab Inc., State College, PA, USA). ORs were used as an approximation of relative risks, using 95% confidence intervals.
The statistical analysis for expression of UGT2B17 mRNA in prostate was done with Mann-Whitney U-test.
Prostate tissue collection and RNA extraction Study participants were selected from patients undergoing radical prostatectomy for localized prostate cancer at the Urology Department, Karolinska University Hospital. Informed consent was obtained from the participants and the Ethics Committee, Karolinska Institutet, approved the study. Immediately after radical prostatectomy, the specimen was sliced horizontally in approximately 4-mm intervals. One of these slices was fresh frozen in liquid nitrogen and stored at À801C before RNA preparation. A total of 15 human prostate tissues were collected and subsequently stained with hematoxylin and eosin. The histopathology was assessed by pathologists. Approximately 25 mg tissues from a nontumour area, mainly from the transition zone were homogenized and total RNA extraction was performed using Amersham (GE-healthcare, Uppsala, Sweden) total RNA Kit. Genomic DNA was prepared from whole blood obtained before surgery (Qiagen, Valencia, CA, USA) and used in genotyping assay as described above. None of the investigated patients were on hormonal therapy.
Quantitative real-time reverse transcriptase RNA (1 mg) was reverse transcribed into cDNA with hexamer primer using first-strand cDNA synthesis kit (Amersham) according to the manufacturer's protocol. Primers specific for UGT2B17 were designed so that the primers spanned over two exons. 18S (Applied Biosystems) was chosen as an endogenous housekeeping control gene. Gene quantitative real-time PCR was performed using the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Reaction mixtures contained 1xSYBR Green PCR master mix (Applied Biosystems), 0.45 mM primers (Table 3 ), 1 ml cDNA template in a total volume of 25 ml. Thermal cycling conditions included activation at 951C (10 min) followed by 40 cycles each of denaturation at 951C (15 s) and annealing/elongation at 601C (1 min).
The real-time PCR analyses were performed twice in duplicate and non-template controls were included in each experiment. A mixed prostate sample was established as a calibrator in the delta CT-formula as described by Livak and Schmittgen. 24 The gene expression was quantified as the yield of the target gene relative to that of 18S gene.
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